Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 377

1.

Systems structural biology measurements by in vivo cross-linking with mass spectrometry.

Chavez JD, Mohr JP, Mathay M, Zhong X, Keller A, Bruce JE.

Nat Protoc. 2019 Aug;14(8):2318-2343. doi: 10.1038/s41596-019-0181-3. Epub 2019 Jul 3.

PMID:
31270507
2.

Grades of brain arteriovenous malformations and risk of hemorrhage and death.

Stefani MA, Sgarabotto Ribeiro D, Mohr JP.

Ann Clin Transl Neurol. 2019 Jan 22;6(3):508-514. doi: 10.1002/acn3.723. eCollection 2019 Mar.

3.

Association between mortality and implantable cardioverter-defibrillators by aetiology of heart failure: a propensity-matched analysis of the WARCEF trial.

Lee TC, Qian M, Mu L, Di Tullio MR, Graham S, Mann DL, Nakanishi K, Teerlink JR, Lip GYH, Freudenberger RS, Sacco RL, Mohr JP, Labovitz AJ, Ponikowski P, Lok DJ, Estol C, Anker SD, Pullicino PM, Buchsbaum R, Levin B, Thompson JLP, Homma S, Ye S; WARCEF Investigators.

ESC Heart Fail. 2019 Apr;6(2):297-307. doi: 10.1002/ehf2.12407. Epub 2019 Feb 27.

4.

Elusive Conformational Dynamics of PPARγ Inactivation Tied Down by Chemical Cross-Linking.

Mohr JP, Bruce JE.

Structure. 2018 Nov 6;26(11):1425-1427. doi: 10.1016/j.str.2018.10.015.

5.

Pathological correlates of brain arterial calcifications.

Shapiro SD, Goldman J, Morgello S, Honig L, Elkind MSV, Marshall RS, Mohr JP, Gutierrez J.

Cardiovasc Pathol. 2019 Jan - Feb;38:7-13. doi: 10.1016/j.carpath.2018.09.003. Epub 2018 Oct 12.

PMID:
30399527
6.

Noninterventional Treatment Options for Stroke.

Hartmann A, Mohr JP.

Neuroimaging Clin N Am. 2018 Nov;28(4):639-648. doi: 10.1016/j.nic.2018.06.006. Review.

PMID:
30322599
7.

Heart Failure Severity and Quality of Warfarin Anticoagulation Control (From the WARCEF Trial).

Lee TC, Qian M, Lip GYH, Di Tullio MR, Graham S, Mann DL, Nakanishi K, Teerlink JR, Freudenberger RS, Sacco RL, Mohr JP, Labovitz AJ, Ponikowski P, Lok DJ, Estol C, Anker SD, Pullicino PM, Buchsbaum R, Levin B, Thompson JLP, Homma S, Ye S; WARCEF Investigators.

Am J Cardiol. 2018 Sep 1;122(5):821-827. doi: 10.1016/j.amjcard.2018.05.024. Epub 2018 Jun 4.

8.

Left atrial volume and cardiovascular outcomes in systolic heart failure: effect of antithrombotic treatment.

Di Tullio MR, Qian M, Thompson JLP, Labovitz AJ, Mann DL, Sacco RL, Pullicino PM, Freudenberger RS, Teerlink JR, Graham S, Lip GYH, Levin B, Mohr JP, Buchsbaum R, Estol CJ, Lok DJ, Ponikowski P, Anker SD, Homma S; WARCEF Investigators.

ESC Heart Fail. 2018 Oct;5(5):800-808. doi: 10.1002/ehf2.12331. Epub 2018 Jul 17.

9.

Brain vascular intima vulnerability among HIV-positive and negative individuals.

Hunter MD, Shenoy A, Dwork A, Elkind MSV, Marshall R, Mohr JP, Morgello S, Gutierrez J.

AIDS. 2018 Sep 24;32(15):2209-2216. doi: 10.1097/QAD.0000000000001943.

10.

Mango: A General Tool for Collision Induced Dissociation-Cleavable Cross-Linked Peptide Identification.

Mohr JP, Perumalla P, Chavez JD, Eng JK, Bruce JE.

Anal Chem. 2018 May 15;90(10):6028-6034. doi: 10.1021/acs.analchem.7b04991. Epub 2018 Apr 27.

11.

Functional impairments for outcomes in a randomized trial of unruptured brain AVMs.

Mohr JP, Overbey JR, von Kummer R, Stefani MA, Libman R, Stapf C, Parides MK, Pile-Spellman J, Moquete E, Moy CS, Vicaut E, Moskowitz AJ, Harkness K, Cordonnier C, Biondi A, Houdart E, Berkefeld J, Klijn CJM, Barreau X, Kim H, Hartmann A; International ARUBA Investigators.

Neurology. 2017 Oct 3;89(14):1499-1506. doi: 10.1212/WNL.0000000000004532. Epub 2017 Sep 6.

12.

Aspirin Does Not Increase Heart Failure Events in Heart Failure Patients: From the WARCEF Trial.

Teerlink JR, Qian M, Bello NA, Freudenberger RS, Levin B, Di Tullio MR, Graham S, Mann DL, Sacco RL, Mohr JP, Lip GYH, Labovitz AJ, Lee SC, Ponikowski P, Lok DJ, Anker SD, Thompson JLP, Homma S; WARCEF Investigators.

JACC Heart Fail. 2017 Aug;5(8):603-610. doi: 10.1016/j.jchf.2017.04.011.

13.

Arteriovenous Malformations of the Brain.

Stapf C, Parides MK, Mohr JP.

N Engl J Med. 2017 Aug 3;377(5):497. doi: 10.1056/NEJMc1707399. No abstract available.

PMID:
28770979
14.

Insights in luteovirid structural biology guided by chemical cross-linking and high resolution mass spectrometry.

Alexander MM, Mohr JP, DeBlasio SL, Chavez JD, Ziegler-Graff V, Brault V, Bruce JE, Heck MC.

Virus Res. 2017 Sep 15;241:42-52. doi: 10.1016/j.virusres.2017.05.005. Epub 2017 May 11.

PMID:
28502641
15.

Resting Heart Rate and Ischemic Stroke in Patients with Heart Failure.

Nakanishi K, Di Tullio MR, Qian M, Thompson JLP, Labovitz AJ, Mann DL, Sacco RL, Pullicino PM, Freudenberger RS, Teerlink JR, Graham S, Lip GYH, Levin B, Mohr JP, Buchsbaum R, Estol CJ, Lok DJ, Ponikowski P, Anker SD, Homma S; WARCEF Investigators.

Cerebrovasc Dis. 2017;44(1-2):43-50. doi: 10.1159/000474958. Epub 2017 Apr 19.

16.

Protein interaction networks at the host-microbe interface in Diaphorina citri, the insect vector of the citrus greening pathogen.

Ramsey JS, Chavez JD, Johnson R, Hosseinzadeh S, Mahoney JE, Mohr JP, Robison F, Zhong X, Hall DG, MacCoss M, Bruce J, Cilia M.

R Soc Open Sci. 2017 Feb 8;4(2):160545. doi: 10.1098/rsos.160545. eCollection 2017 Feb.

17.

Histopathological Differences Between the Anterior and Posterior Brain Arteries as a Function of Aging.

Roth W, Morgello S, Goldman J, Mohr JP, Elkind MS, Marshall RS, Gutierrez J.

Stroke. 2017 Mar;48(3):638-644. doi: 10.1161/STROKEAHA.116.015630. Epub 2017 Feb 14.

18.

CHA2 DS2 -VASc score and adverse outcomes in patients with heart failure with reduced ejection fraction and sinus rhythm.

Ye S, Qian M, Zhao B, Buchsbaum R, Sacco RL, Levin B, Di Tullio MR, Mann DL, Pullicino PM, Freudenberger RS, Teerlink JR, Mohr JP, Graham S, Labovitz AJ, Estol CJ, Lok DJ, Ponikowski P, Anker SD, Lip GY, Thompson JL, Homma S; WARCEF Investigators.

Eur J Heart Fail. 2016 Oct;18(10):1261-1266. doi: 10.1002/ejhf.613. Epub 2016 Jul 21.

19.

Left Ventricular Ejection Fraction and Risk of Stroke and Cardiac Events in Heart Failure: Data From the Warfarin Versus Aspirin in Reduced Ejection Fraction Trial.

Di Tullio MR, Qian M, Thompson JL, Labovitz AJ, Mann DL, Sacco RL, Pullicino PM, Freudenberger RS, Teerlink JR, Graham S, Lip GY, Levin B, Mohr JP, Buchsbaum R, Estol CJ, Lok DJ, Ponikowski P, Anker SD, Homma S; WARCEF Investigators.

Stroke. 2016 Aug;47(8):2031-7. doi: 10.1161/STROKEAHA.116.013679. Epub 2016 Jun 28.

20.

Brain arterial aging and its relationship to Alzheimer dementia.

Gutierrez J, Honig L, Elkind MS, Mohr JP, Goldman J, Dwork AJ, Morgello S, Marshall RS.

Neurology. 2016 Apr 19;86(16):1507-15. doi: 10.1212/WNL.0000000000002590. Epub 2016 Mar 16.

21.

Clinical and Echocardiographic Factors Associated With New-Onset Atrial Fibrillation in Heart Failure - Subanalysis of the WARCEF Trial.

Kato TS, Di Tullio MR, Qian M, Wu M, Thompson JL, Mann DL, Sacco RL, Pullicino PM, Freudenberger RS, Teerlink JR, Graham S, Lip GY, Levin B, Mohr JP, Labovitz AJ, Estol CJ, Lok DJ, Ponikowski P, Anker SD, Homma S; WARCEF Investigators.

Circ J. 2016;80(3):619-26. doi: 10.1253/circj.CJ-15-1054. Epub 2016 Jan 22.

22.

The first prognostic model for stroke and death in patients with systolic heart failure.

Freudenberger RS, Cheng B, Mann DL, Thompson JL, Sacco RL, Buchsbaum R, Sanford A, Pullicino PM, Levin B, Teerlink JR, Graham S, Mohr JP, Labovitz AJ, Di Tullio MR, Lip GY, Estol CJ, Lok DJ, Ponikowski P, Anker SD, Homma S; WARCEF Investigators.

J Cardiol. 2016 Aug;68(2):100-3. doi: 10.1016/j.jjcc.2015.09.014. Epub 2015 Nov 6.

23.

Antiphospholipid Antibodies and Recurrent Thrombotic Events: Persistence and Portfolio.

Amory CF, Levine SR, Brey RL, Gebregziabher M, Tuhrim S, Tilley BC, Simpson AC, Sacco RL, Mohr JP; APASS-WARSS Collaborators.

Cerebrovasc Dis. 2015;40(5-6):293-300. doi: 10.1159/000441362. Epub 2015 Oct 29.

24.

Bleeding Risk and Antithrombotic Strategy in Patients With Sinus Rhythm and Heart Failure With Reduced Ejection Fraction Treated With Warfarin or Aspirin.

Ye S, Cheng B, Lip GY, Buchsbaum R, Sacco RL, Levin B, Di Tullio MR, Qian M, Mann DL, Pullicino PM, Freudenberger RS, Teerlink JR, Mohr JP, Graham S, Labovitz AJ, Estol CJ, Lok DJ, Ponikowski P, Anker SD, Thompson JL, Homma S; WARCEF Investigators.

Am J Cardiol. 2015 Sep 15;116(6):904-12. doi: 10.1016/j.amjcard.2015.06.016. Epub 2015 Jun 24.

25.

José Luis Martí Vilalta (1946-2014).

Kase CS, Mohr JP, Martí-Fàbregas J.

Cerebrovasc Dis. 2015;40(1-2):99. doi: 10.1159/000437011. Epub 2015 Jul 11. No abstract available.

26.

A Functional Perspective on the Embryology and Anatomy of the Cerebral Blood Supply.

Menshawi K, Mohr JP, Gutierrez J.

J Stroke. 2015 May;17(2):144-58. doi: 10.5853/jos.2015.17.2.144. Epub 2015 May 29. Review.

27.

Management of unbled brain arteriovenous malformation study.

Mohr JP, Yaghi S.

Neurol Clin. 2015 May;33(2):347-59. doi: 10.1016/j.ncl.2014.12.006. Review.

28.

Acute management of brain arteriovenous malformations.

Hartmann A, Mohr JP.

Curr Treat Options Neurol. 2015 May;17(5):346. doi: 10.1007/s11940-015-0346-5.

PMID:
25854649
29.

Quality of anticoagulation control in preventing adverse events in patients with heart failure in sinus rhythm: Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction trial substudy.

Homma S, Thompson JL, Qian M, Ye S, Di Tullio MR, Lip GY, Mann DL, Sacco RL, Levin B, Pullicino PM, Freudenberger RS, Teerlink JR, Graham S, Mohr JP, Labovitz AJ, Buchsbaum R, Estol CJ, Lok DJ, Ponikowski P, Anker SD; WARCEF Investigators.

Circ Heart Fail. 2015 May;8(3):504-9. doi: 10.1161/CIRCHEARTFAILURE.114.001725. Epub 2015 Apr 7.

30.

Viewpoints on the ARUBA trial.

Mohr JP, Hartmann A, Kim H, Pile-Spellman J, Stapf C.

AJNR Am J Neuroradiol. 2015 Apr;36(4):615-7. doi: 10.3174/ajnr.A4204. Epub 2014 Dec 26. No abstract available.

31.

Association of quality of life with anticoagulant control in patients with heart failure: the Warfarin and Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) trial.

Shaffer JA, Thompson JL, Cheng B, Ye S, Lip GY, Mann DL, Sacco RL, Pullicino PM, Freudenberger RS, Graham S, Mohr JP, Labovitz AJ, Estol CJ, Lok DJ, Ponikowski P, Anker SD, Di Tullio MR, Homma S; WARCEF Investigators.

Int J Cardiol. 2014 Dec 15;177(2):715-7. No abstract available.

32.

Cognitive function in ambulatory patients with systolic heart failure: insights from the warfarin versus aspirin in reduced cardiac ejection fraction (WARCEF) trial.

Graham S, Ye S, Qian M, Sanford AR, Di Tullio MR, Sacco RL, Mann DL, Levin B, Pullicino PM, Freudenberger RS, Teerlink JR, Mohr JP, Labovitz AJ, Lip GY, Estol CJ, Lok DJ, Ponikowski P, Anker SD, Thompson JL, Homma S; WARCEF Investigators.

PLoS One. 2014 Nov 26;9(11):e113447. doi: 10.1371/journal.pone.0113447. eCollection 2014.

33.

Recurrent stroke in the warfarin versus aspirin in reduced cardiac ejection fraction (WARCEF) trial.

Pullicino PM, Qian M, Sacco RL, Freudenberger R, Graham S, Teerlink JR, Mann D, Di Tullio MR, Ponikowski P, Lok DJ, Anker SD, Lip GY, Estol CJ, Levin B, Mohr JP, Thompson JL, Homma S; WARCEF Investigators.

Cerebrovasc Dis. 2014;38(3):176-81. doi: 10.1159/000365502. Epub 2014 Oct 9.

34.

Acute cervical myelopathy due to presumed fibrocartilaginous embolism: a case report and systematic review of the literature.

Cuello JP, Ortega-Gutierrez S, Linares G, Agarwal S, Cunningham A, Mohr JP, Mayer SA, Marshall RS, Claassen J, Badjatia N, Elkind MS, Lee K.

J Spinal Disord Tech. 2014 Dec;27(8):E276-81. doi: 10.1097/BSD.0000000000000115. Review.

PMID:
24901879
35.

Management of brain arteriovenous malformations--authors' reply.

Stapf C, Parides MK, Moskowitz AJ, Mohr JP.

Lancet. 2014 May 10;383(9929):1635-1636. doi: 10.1016/S0140-6736(14)60786-8. No abstract available.

PMID:
24814454
36.

Results of ARUBA are applicable to most patients with nonruptured arteriovenous malformations.

Mohr JP.

Stroke. 2014 May;45(5):1541-2. doi: 10.1161/STROKEAHA.113.002698. Epub 2014 Mar 11. No abstract available.

37.

Medical management with or without interventional therapy for unruptured brain arteriovenous malformations (ARUBA): a multicentre, non-blinded, randomised trial.

Mohr JP, Parides MK, Stapf C, Moquete E, Moy CS, Overbey JR, Al-Shahi Salman R, Vicaut E, Young WL, Houdart E, Cordonnier C, Stefani MA, Hartmann A, von Kummer R, Biondi A, Berkefeld J, Klijn CJ, Harkness K, Libman R, Barreau X, Moskowitz AJ; international ARUBA investigators.

Lancet. 2014 Feb 15;383(9917):614-21. doi: 10.1016/S0140-6736(13)62302-8. Epub 2013 Nov 20.

38.

History of transient ischemic attack definition.

Mohr JP.

Front Neurol Neurosci. 2014;33:1-10. doi: 10.1159/000351883. Epub 2013 Oct 11. Review.

PMID:
24157552
39.

Stroke in heart failure in sinus rhythm: the Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction trial.

Pullicino PM, Thompson JL, Sacco RL, Sanford AR, Qian M, Teerlink JR, Haddad H, Diek M, Freudenberger RS, Labovitz AJ, Di Tullio MR, Lok DJ, Ponikowski P, Anker SD, Graham S, Mann DL, Mohr JP, Homma S; WARCEF Investigators.

Cerebrovasc Dis. 2013;36(1):74-8. doi: 10.1159/000352058. Epub 2013 Jul 30.

40.

Benefit of warfarin compared with aspirin in patients with heart failure in sinus rhythm: a subgroup analysis of WARCEF, a randomized controlled trial.

Homma S, Thompson JL, Sanford AR, Mann DL, Sacco RL, Levin B, Pullicino PM, Freudenberger RS, Teerlink JR, Graham S, Mohr JP, Massie BM, Labovitz AJ, Di Tullio MR, Gabriel AP, Lip GY, Estol CJ, Lok DJ, Ponikowski P, Anker SD; WARCEF Investigators.

Circ Heart Fail. 2013 Sep 1;6(5):988-97. doi: 10.1161/CIRCHEARTFAILURE.113.000372. Epub 2013 Jul 23.

41.

Temporary is not always benign: similarities and differences between transient ischemic attack and angina.

Carolei A, Pistoia F, Sacco S, Mohr JP.

Mayo Clin Proc. 2013 Jul;88(7):708-19. doi: 10.1016/j.mayocp.2013.04.014. Review.

PMID:
23809319
42.

In memoriam: charles miller fisher, MD (1913-2012).

Caplan LR, Mohr JP, Ackerman RH.

Arch Neurol. 2012 Sep 1;69(9):1208-9. doi: 10.1001/archneurol.2012.1743. No abstract available.

PMID:
23753916
43.

Efficacy and safety of vorapaxar in patients with prior ischemic stroke.

Morrow DA, Alberts MJ, Mohr JP, Ameriso SF, Bonaca MP, Goto S, Hankey GJ, Murphy SA, Scirica BM, Braunwald E; Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events–TIMI 50 Steering Committee and Investigators.

Stroke. 2013 Mar;44(3):691-8. doi: 10.1161/STROKEAHA.111.000433. Epub 2013 Feb 8.

PMID:
23396280
44.

Amino terminal pro-B-type natriuretic peptide, secondary stroke prevention, and choice of antithrombotic therapy.

Longstreth WT Jr, Kronmal RA, Thompson JL, Christenson RH, Levine SR, Gross R, Brey RL, Buchsbaum R, Elkind MS, Tirschwell DL, Seliger SL, Mohr JP, deFilippi CR.

Stroke. 2013 Mar;44(3):714-9. doi: 10.1161/STROKEAHA.112.675942. Epub 2013 Jan 22.

45.

Diagnosis and treatment of arteriovenous malformations.

Mohr JP, Kejda-Scharler J, Pile-Spellman J.

Curr Neurol Neurosci Rep. 2013 Feb;13(2):324. doi: 10.1007/s11910-012-0324-1. Review.

PMID:
23307509
46.

Stroke after carotid stenting and endarterectomy in the Carotid Revascularization Endarterectomy versus Stenting Trial (CREST).

Hill MD, Brooks W, Mackey A, Clark WM, Meschia JF, Morrish WF, Mohr JP, Rhodes JD, Popma JJ, Lal BK, Longbottom ME, Voeks JH, Howard G, Brott TG; CREST Investigators.

Circulation. 2012 Dec 18;126(25):3054-61. doi: 10.1161/CIRCULATIONAHA.112.120030. Epub 2012 Nov 16.

47.

Cerebrovascular malformations: seizure risk with AVMs--medical vs interventional management.

Mohr JP.

Nat Rev Neurol. 2012 Oct;8(10):535-6. doi: 10.1038/nrneurol.2012.195. Epub 2012 Sep 18. No abstract available.

PMID:
22986436
48.

C.M. Fisher--master clinician.

Mohr JP.

Cerebrovasc Dis. 2012;33(6):594-6. doi: 10.1159/000339193. Epub 2012 Jun 14. No abstract available.

49.

Hull down on the horizon: A Randomized trial of Unruptured Brain Arteriovenous malformations (ARUBA) trial.

Mohr JP, Moskowitz AJ, Parides M, Stapf C, Young WL.

Stroke. 2012 Jul;43(7):1744-5. doi: 10.1161/STROKEAHA.112.653584. Epub 2012 Jun 5. No abstract available.

PMID:
22669405
50.

Warfarin and aspirin in patients with heart failure and sinus rhythm.

Homma S, Thompson JL, Pullicino PM, Levin B, Freudenberger RS, Teerlink JR, Ammon SE, Graham S, Sacco RL, Mann DL, Mohr JP, Massie BM, Labovitz AJ, Anker SD, Lok DJ, Ponikowski P, Estol CJ, Lip GY, Di Tullio MR, Sanford AR, Mejia V, Gabriel AP, del Valle ML, Buchsbaum R; WARCEF Investigators.

N Engl J Med. 2012 May 17;366(20):1859-69. doi: 10.1056/NEJMoa1202299. Epub 2012 May 2.

Supplemental Content

Support Center